PARSIPPANY, N.J. and TEL AVIV, Israel and PARIS, Feb. 20, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), and Medincell (Euronext: MEDCL), announced today that the U.S. Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) for olanzapine extended-release injectable suspension (TEV-'749) for the treatment of schizophrenia in adults. TEV-'749 is designed to improve real-world treatment adherence and help patients maintain long-term stability, with the goal of addressing a critical treatment gap for people living with schizophrenia.

Teva Pharmaceutical Industries (TEVA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Corcept had argued that Teva's label for its generic version of Korlym, a drug used to treat Cushing's syndrome, would induce doctors to follow patented dosing methods involving mifepristone and strong CYP3A inhibitors such as ketoconazole.

Guru Stock PicksLouis Moore Bacon has made the following transactions:Reduce in XLF by 69.62%Sold out in CEGAdd in CLS by 386.7%New position in CLJoel Greenblat

Insights into Glenview Capital Management's Fourth Quarter 2025 Moves Larry Robbins (Trades, Portfolio) recently submitted the 13F filing for the fourth quarte

Teva Pharmaceutical Industries Limited (TEVA) Discusses Duvakitug IBD Phase 2b Maintenance Top-Line Results Transcript

Teva and Sanofi SA (NASDAQ: SNY) released positive results on Tuesday from the RELIEVE UCCD long-term extension study of duvakitug, an investigational human monoclonal antibody targeting TL1A.

Teva will hold an investor call and live webcast today, Tuesday, February 17, 2026, at 8:00 a.m. ET to discuss these data.

Thrivent Financial for Lutherans purchased a new position in shares of Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund purchased 199,467 shares of the company's stock, valued at approximately $4,029,000. A number of other

Exploring the Strategic Moves of a Renowned Value Investor Francisco Garcia Parames (Trades, Portfolio), a prominent figure in the world of value investing, re